Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

Melanoma is the deadliest form of skin cancer, primarily due to its high metastatic propensity and therapeutic resistance in advanced stages. The frequent inactivation of the p53 tumour suppressor protein in melanomagenesis may predict promising outcomes for p53 activators in melanoma therapy. Herei...

Full description

Bibliographic Details
Main Authors: Joana B. Loureiro, Liliana Raimundo, Juliana Calheiros, Carla Carvalho, Valentina Barcherini, Nuno R. Lima, Célia Gomes, Maria Inês Almeida, Marco G. Alves, José Luís Costa, Maria M. M. Santos, Lucília Saraiva
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
melanoma
metastasis
drug resistance
targeted therapy
p53
tryptophanol-derived oxazoloisoindolinone
Online Access:https://www.mdpi.com/2072-6694/13/7/1648

Internet

https://www.mdpi.com/2072-6694/13/7/1648

Similar Items